论文部分内容阅读
目的:探讨急性脑梗死的常规治疗和加用依达拉奉治疗的疗效变化。方法:100例急性脑梗死患者随机分为治疗组和对照组,每组各50例,对照组用常规治疗方法(灯盏花和胞二磷胆碱静滴,口服阿司匹林等治疗),治疗组在常规治疗基础上加用生理盐水250 mL+依达拉奉注射液30 mg静脉滴注,每日2次,7~14天为1个疗程,进行疗效评定。治疗前、治疗后14天和21天对患者进行欧洲卒中评分(ESS)、日常生活活动能力(ADL)评定。通过增分率判断疗效,同时记录不良反应。结果:治疗组14天和21天评定ESS的有效率分别为78.0%和84.0%,对照组为52.0%和58.0%;14天和21天评定ADL的有效率治疗组为80.0%和88.0%,对照组为56.0%和66.0%;治疗组无明显不良反应.结论:依达拉奉治疗急性脑梗死安全有效。
Objective: To investigate the conventional treatment of acute cerebral infarction and add edaravone treatment efficacy changes. Methods: One hundred patients with acute cerebral infarction were randomly divided into treatment group and control group, with 50 cases in each group. The control group was treated with conventional therapy (Erigeron and Citicoline intravenous infusion, oral aspirin and other treatment) On the basis of conventional treatment plus saline 250 mL + edaravone 30 mg intravenously, 2 times a day, 7 to 14 days for a course of treatment, the efficacy evaluation. Patients were assessed for European stroke score (ESS), daily living activity (ADL) before treatment, on days 14 and 21 after treatment. Judgment of efficacy by increasing the score, while recording adverse reactions. Results: The effective rate of ESS was 78.0% and 84.0% on the 14th and 21th days in the treatment group, 52.0% and 58.0% in the control group, 80.0% and 88.0% on the 14th and 21st days, respectively. The control group was 56.0% and 66.0%, the treatment group had no significant adverse reactions.Conclusion: Edaravone is safe and effective in the treatment of acute cerebral infarction.